Kymera Therapeutics, Inc.
KYMR
Rangering i aksjer
#2179
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Aksjekurs
$114.06
Sist synkronisert: 2026-10-20
Markedsverdi
$9.38B
Endring (1 dag)
5.54%
Endring (1 år)
95.57%
Land
US
Handel Kymera Therapeutics, Inc. (KYMR)
Kategori
Healthcare
Antall utestående aksjer for Kymera Therapeutics, Inc. (KYMR)
Antall utestående aksjer per June 2026: 98.18M
Ifølge Kymera Therapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 98.18M. Ved slutten av December 2023 hadde selskapet 58.37M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Kymera Therapeutics, Inc. (KYMR) fra 2018 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 98.18M | 30.83% |
| 2024 | 75.04M | 28.58% |
| 2023 | 58.37M | 8.22% |
| 2022 | 53.93M | 12.39% |
| 2021 | 47.99M | 7.70% |
| 2020 | 44.56M | 0.06% |
| 2019 | 44.53M | 0.00% |
| 2018 | 44.53M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 158.61% |
US
|
|
| 396.00M | 303.35% |
US
|
|
| 478.91M | 387.80% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -36.66% |
NL
|
